PACIRA BIOSCIENCES INCORPORATED (PCRX)

SpaceX stock whipsawed through a volatile week, swinging from an all-time low to a sharp rebound and closing at a new low, as investors braced for the newly public company's first earnings report and a major share unlock.

Purchase price of approximately $8.1 millionAcquisition increases PharmaCorp's operating network to 15 pharmacies Previously announced second definitive share purchase agreement has received preliminary college approval and is anticipated to...

Parex Resources Inc. reported Q2 2026 net income of $444 million, largely driven by a $302 million gain on the Frontera E&P acquisition. Average production increased to 54,121 boe/d, up from 44,735 boe/d in Q1. Adjusted FFO was $191 million. The company reaffirmed H2 2026 production guidance ...

The last earnings report on July 30 showed earnings per share of 37 cents, beating the estimate of -7 cents. With 6.85M shares outstanding, the current market capitalization sits at 387.15M.

Pacira BioSciences (NASDAQ:PCRX) will be releasing its Q2 2026 earnings after the market closes on Tuesday, August 4. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-8-4-pacira-biosciences-inc-stock/)